Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Invion. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Invion's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Invion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Invion's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Invion's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Invion's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Invion is high growth as no earnings estimate data is available.
Unable to determine if Invion is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Invion's filings and announcements here.
Invion's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Craig Newton has been Chief Executive Officer at Invion Ltd since November 1, 2019 and also has been its Managing Director and Director since November 2019 and November 4, 2019 respectively. He was Chief Operating Officer at Invion Ltd since joining in April 2018 until November 1, 2019. He has recruited a strong and experienced clinical development team. He served as Chief Operating Officer of Cryptome Pharmaceuticals Ltd. He has solid experience in senior business and operational roles gained at various leading global companies including CSL, Serono UK, Bio Nova International, AVAX Australia and Cryptome Pharmaceuticals. He has held senior commercial and management roles at large multinational pharmaceutical companies and small biotechs, including a number of years in the UK industry. His experience covers marketing strategy and implementation, commercial assessment, international business development, project management and laboratory and salesforce management. Mr. Newton was previously Sales and Marketing Director at AVAX Australia, an Australian-based start-up which launched a cancer vaccine based on US technology. Prior to AVAX, he worked in the UK at Ares-Serono, Europe's largest biotechnology company, where he managed the GBP20m Reproductive Health Division. Previously, he worked at CSL Limited, where he developed new marketing programs and launched products in Australia and Asia.
Insufficient data for Craig to compare compensation growth.
Craig's remuneration is lower than average for companies of similar size in United States of America.
MD, CEO & Director
Head of Intellectual Property Development
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Invion board of directors is less than 3 years, this suggests a new board.
Board of Directors
MD, CEO & Director
Member of Scientific & Medical Advisory Board
Member of Scientific Advisory Board
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Invion Limited, a clinical-stage life-sciences company, develops photodynamic therapy for the treatment of various cancers in Australia. It develops IVX-P02 to treat skin cancers, as well as solid cancers, including lung, prostrate, and ovarian cancers; and IVX-MES, an intravenous treatment for mesothelioma. The company has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and partnership agreements with Formulytica and vivoPharm to develop and test IVX-P02 gel. Invion Limited also has a research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company is headquartered in Melbourne, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.